The Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins is dedicated to cancer research, education and training, and care, with an overarching goal of expeditiously and strategically applying new knowledge to improve prevention, screening, detection, diagnosis and treatment of cancer in Maryland and throughout nation and the world. Through targeted outreach and research, cancer outcomes disparities are decreasing in SKCCC's catchment area, but they remain a challenge and a focus at SKCCC. This application requests continued Cancer Center Support Grant (CCSG) funding for SKCCC's Research Programs and Cores. The SKCCC comprises a multidisciplinary, interdepartmental center of The Johns Hopkins University (JHU), encompassing 34 departments in five schools. The scientific Programs of the SKCCC organize and orient the broad base of cancer research throughout JHU into teams focused on rapid translation to the clinic and to populations inside and outside its catchment area. Research conducted at SKCCC includes discovery research into the molecular genetics of human tumorigenesis, clinical trials of new cancer treatments and epidemiologic analyses of lifestyle influences on cancer mortality. The SKCCC is a leading cancer center that is providing insights into the fundamental nature of different cancers and elucidating the thousands of somatic genetic and epigenetic alterations that mark the differences from case to case. This body of work has fueled an emerging understanding that the ultimate control of cancer will require individualizing cancer care using approaches that can be deployed at a population scale. To accomplish this mission, SKCCC took critical input from its External Advisory Board and has strategically evolved since the last CCSG to: 1) augment the clinical and population impact of the discovery pipeline in cancer genetics, epigenetics and immunology generated by discipline-oriented Programs; 2) maximize the translational research output of disease-specific Programs, emphasizing the exploration of new concepts in scientifically driven clinical trials; and 3) position the population-oriented Program to identify, understand and overcome barriers responsible for disparities in cancer outcome in the catchment area. The nine SKCCC Research Programs include four discipline-oriented Programs: Cancer Biology (CB; Baylin, Velculescu), Cancer Immunology (CI; Pardoll, Drake), Cancer Molecular and Functional Imaging (CMFI; Bhujwalla, Pomper), and Cancer Chemical and Structural Biology (CCSB; Berger, Liu); four disease- specific Programs: Hematologic Malignancies and Bone Marrow Transplantation (HMBMT; Ambinder, Jones, Levis), Prostate Cancer (PC; Pienta, Denmeade, Lupold), Breast and Ovarian Cancer (BOC; Stearns, Shih), and Brain Cancer (BC; Grossman, Brem, Laterra); and one population-oriented Program: Cancer Prevention and Control (CPC; Platz, Roden). These Programs are supported by fifteen Cores, one developing Core (described in Developmental Funds) and a dedicated leadership team.

Public Health Relevance

(Public Health Relevance Statement) Cancer is a leading cause of death in the U.S. and throughout the world. With the tremendous medical advances over the past 50 years, the U.S. population's life expectancy has dramatically increased, but because the incidence of most cancers increases with age, cancers have become a profound challenge to the U.S. health care system. Minorities suffer a disproportionate burden of the cancer threat with disparate outcomes for many cancer types. To meet these challenges, dedicated cancer research at the SKCCC and elsewhere over the past 35 years has generated fundamental insights into the molecular mechanisms that cause human cancers to arise, progress and threaten life. These discoveries create new opportunities to improve screening, detection, diagnosis, prevention and treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-57
Application #
9944458
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
1997-05-07
Project End
2022-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
57
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663

Showing the most recent 10 out of 2393 publications